Proventa’s Weekly Round-up – 10/1/19
Happy new year! It’s a fairly slow week as the sector takes stock and begins to get back, with annual price rises the main event in the news - big pharma has announced its regular price increases for the new...
7 years agoProventa’s Weekly Round-up – 10/1/19
Happy new year! It’s a fairly slow week as the sector takes stock and begins to get back, with annual price rises the main event in the news - big pharma has announced its regular price increases for the new...
7 years ago

The Future of Organ-on-a-Chip
Dozens of solutions have been suggested to lessen the crisis that has been hitting pharma R&D recently. Over the last decade, the cost of creating drugs has skyrocketed even as the amount of new medicines reaching market is steadily declining....
7 years agoThe Future of Organ-on-a-Chip
Dozens of solutions have been suggested to lessen the crisis that has been hitting pharma R&D recently. Over the last decade, the cost of creating drugs has skyrocketed even as the amount of new medicines reaching market is steadily declining....
7 years ago



Proventa’s Weekly Round-up – 20/12/19
Merry Christmas! This week in our segment on “the same three stories every week that are of broad general interest”, Trump’s administration has made an attempt to reduce U.S. drug prices with a plan to allow Canadian imports; Nancy Pelosi’s...
7 years agoProventa’s Weekly Round-up – 20/12/19
Merry Christmas! This week in our segment on “the same three stories every week that are of broad general interest”, Trump’s administration has made an attempt to reduce U.S. drug prices with a plan to allow Canadian imports; Nancy Pelosi’s...
7 years ago



Proventa’s Weekly Round-up – 13/12/19
Avoiding yesterday’s election and all it means for the UK and Brexit, much of the news this week happened across the pond: Pharma companies have reacted violently to the Republicans’ alleged reneging of drug patent rules in international negotiations, while...
7 years agoProventa’s Weekly Round-up – 13/12/19
Avoiding yesterday’s election and all it means for the UK and Brexit, much of the news this week happened across the pond: Pharma companies have reacted violently to the Republicans’ alleged reneging of drug patent rules in international negotiations, while...
7 years ago

AI and Pharmacovigilance ADR processing
Many of the problems that have long been inherent in Pharmacovigilance (PV) - such as historic limitations in the information that is published in case reports, analysis of electronic health records and integration - have found an answer in the...
7 years agoAI and Pharmacovigilance ADR processing
Many of the problems that have long been inherent in Pharmacovigilance (PV) - such as historic limitations in the information that is published in case reports, analysis of electronic health records and integration - have found an answer in the...
7 years ago

Time to invest in CGT: Its Benefits for Pharma
The concept of cell and gene therapy (CGT), wherein scientists and healthcare experts adapt cells and genes to treat illnesses, is nothing new in the life science space. Even the relatively new CRISPR has transformed into a household buzzword over...
7 years agoTime to invest in CGT: Its Benefits for Pharma
The concept of cell and gene therapy (CGT), wherein scientists and healthcare experts adapt cells and genes to treat illnesses, is nothing new in the life science space. Even the relatively new CRISPR has transformed into a household buzzword over...
7 years agoInterested?
Reserve your space

